Frequently Asked Questions (FAQs) for Health Care Providers about Ebola Virus Disease

1. **Why is Ebola Virus Disease so concerning?**

Ebola is a filovirus that can be transmitted by contact with infected body fluids, has no recognized treatment other than supportive care, and has a very high mortality rate (60-90%). Of note, less than 50% of patients have hemorrhage, especially early in the illness. Healthcare providers in Africa sometimes become infected because of exposure to the patient prior to diagnosis, or the inability to protect themselves through appropriate policies and personal protective equipment.

2. **How extensive is the Ebola outbreak in Guinea and Liberia?**

Compared with the other Ebola outbreaks in Africa since 1976, this outbreak is more geographically widespread involving 6 districts (five rural) and 20 patients in one major city (Conarky, the capital of Guinea). See color map of outbreak zones at: http://www.afro.who.int/en/clusters-a-programmes/dpc/epidemic-a-pandemic-alert-and-response/outbreak-news/4087-ebola-virus-disease-west-africa-7-april-2014.html. As of 7 April, a cumulative total of 151 clinically compatible cases, including 95 deaths had officially been reported from Guinea. 14 of the cases including 8 deaths are health workers (11 are laboratory confirmed cases). Medical observation is continuing for 535 contacts. Liberia has reported a cumulative total of 5 laboratory confirmed cases and 16 suspected and probable cases of Ebola virus disease (EVD), including 10 deaths. Three cases have occurred in health-care workers, all of whom have died. See updates on the WHO website at: http://www.who.int/csr/don/en/

3. **What is the strain of Ebola causing this outbreak?**

Zaire strain (98% match), the most lethal strain of Ebola. (approximately 60% of patients in the current outbreak and higher in prior Zaire strain outbreaks in Africa) There is little or no clinical experience with Ebola patients being treated in modern ICUs, thus mortality here may be lower.

4. **What is the incubation period?**

From 2-21 days after exposure. CDC states that 8-10 days is most common

5. **Is the virus contagious before illness onset?**

No. It is contagious only after illness onset (e.g., fever)

6. **How is the virus transmitted from person-to-person?**

By contact with infected body fluids, especially blood (including via needles) but also urine, vomitus, stool, and soiled linen. Patients in Africa often have had exposures to several such body fluids. Thus, it is sometimes difficult to be certain how infection occurred.

7. **What should we look for in a suspect case in the USA?**

(1) Travel from Guinea or Liberia outbreak areas within 21 days of illness onset.
(2) Contact with suspected or confirmed Ebola Virus Disease (EVD) patient within 21 days of illness onset.

8. **What are the symptoms and signs to look for?**

The CDC Ebola fact sheet lists 2 sets of signs & symptoms:

(1) Symptoms “typically include: Fever, headache, vomiting, stomach pain, and lack of appetite”.
(2) “Some patients may experience: A rash, red eyes, hiccups, cough, sore throat, chest pain, difficulty breathing, difficulty swallowing, bleeding inside and outside the body.”
9. What patient should I suspect of having Ebola virus (& initiate reporting to local public health)? Patients with a travel and/or exposure history AND a clinical presentation consistent with the above CDC description. *When more specific CDC or local Health Department guidance is given, then it should be adopted.


10. During this outbreak have any suspected patients been reported in North America? One patient traveling to Canada was reported March 25th to have tested negative for Ebola virus. One patient traveling from West Africa was hospitalized March 31 in Minneapolis and reported to be infected with Lassa fever virus (not Ebola). Statistically, the risk of a traveler to the USA having Ebola virus is very low. The risk of a traveler being suspected of having Ebola in the differential diagnosis is higher, however, and warrants enhanced Ebola preparedness.

11. Is there an FDA-licensed prophylaxis, or a treatment? No, only investigational ones (none of which include efficacy data in humans to our knowledge)

12. What initial actions should be taken, and what personal protective equipment should be worn?

1. Immediately place any suspected patient into an isolation room. Until the disease process is defined, an airborne isolation (AIIR) room is recommended. Patients with respiratory symptoms should wear a simple mask.

2. Adopt strict contact precautions and pay particular attention to safe doffing, or removal of PPE. Use of a simple mask and faceshield is appropriate although providers may opt for N95 mask until the pathogen is confirmed.

3. Contact Infection Prevention and Control and Infectious Disease on-call immediately and assure that the local/state health department is involved as well for appropriate sample acquisition and tracking.

4. Minimize the number of caregivers and invasive procedures to decrease exposure opportunities.

5. Assure special precautions for handling laboratory samples and for personnel performing testing (including notification of lab personnel, special labeling, handling, and containers, etc.)

Note that once Ebola is confirmed, infection control precautions move to strict contact precautions and private, but not respiratory isolation rooms. See the current online CDC “Prevention” guidance for Ebola http://www.cdc.gov/vhf/ebola/prevention/index.html for further information on PPE, disinfection / sterilization of equipment and spaces, and isolation procedures.

Also, see the detailed 4-page most recent (2005) CDC information on “Infection Control Precautions” and PPE contained in the document titled “Interim Guidance for Managing patients with Suspected Viral Hemorrhagic Fever in U.S. Hospitals” at: http://www.cdc.gov/vhf/ebola/vhf-interim-guidance.pdf This guidance includes more detailed information on infection prevention and control as well as laboratory handling and addresses special circumstances and options for PPE.

Please contact Dr. Daniel Lucey (DRL23@Georgetown.edu) for any factual or contextual errors in this FAQ.

Dr. Daniel Lucey, Dr. John Hick, and Dr. Dan Hanfling developed this document as courtesy information for healthcare providers. This information does not constitute clinical guidance or policy and facilities may modify this document as required to reflect their specific needs and circumstances. The authors bear no responsibility for the use of this information by a healthcare provider or facility.